- Conditions
- Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
- Interventions
- FOLFOX, 5-FU, Erlotinib
- Drug
- Lead sponsor
- Translational Oncology Research International
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 394
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Colorectal Cancer
- Interventions
- Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
- Conditions
- Colorectal Cancer
- Interventions
- Arsenic trioxide, Fluorouracil, Leucovorin calcium, Plasma levels of elemental arsenic, Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis, Tumor Biopsy (Fine-Needle Aspiration)
- Drug · Other · Genetic + 1 more
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
- Interventions
- PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 9
- States / cities
- Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more
- Conditions
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
- Interventions
- Anvumetostat, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX, RMC-6236
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 29
- States / cities
- Bakersfield, California • Duarte, California • La Jolla, California + 24 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase, Biospecimen Collection, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Lestaurtinib, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Pegaspargase, Pharmacological Study, Prednisone, Therapeutic Hydrocortisone, Vincristine Sulfate
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 1 Year
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2024
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 120 more
- Conditions
- Chemotherapeutic Agent Toxicity, Colorectal Cancer, Neuropathy, Neurotoxicity
- Interventions
- calcium gluconate, magnesium sulfate, placebo, oxaliplatin
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 404
- States / cities
- Fairbanks, Alaska • Antioch, California • Fairfield, California + 278 more
- Conditions
- Leukemia, Lymphoma, Sarcoma
- Interventions
- leucovorin calcium, trimetrexate glucuronate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia
- Interventions
- cytarabine, dexamethasone, etoposide, idarubicin, ifosfamide, leucovorin calcium, mesna, pegaspargase, therapeutic hydrocortisone, thioguanine, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy, Methotrexate
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2006
- U.S. locations
- 30
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 23 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Interventions
- FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 508
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Interventions
- 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Nelfinavir Mesylate, Oregovomab, Stereotactic Body Radiation Therapy, Therapeutic Conventional Surgery
- Procedure · Drug · Other + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib
- Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- oxaliplatin, leucovorin calcium, fluorouracil, capecitabine, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 154
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Auburn, California + 112 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Leucovorin calcium
- Drug
- Lead sponsor
- U.S. Bioscience
- Industry
- Eligibility
- 2 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- West Conshohocken, Pennsylvania
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel
- Drug · Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- El Segundo, California
- Conditions
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
- Interventions
- Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 453
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 276 more
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Interventions
- Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate
- Drug · Device · Biological
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Adult Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- allopurinol, cyclophosphamide, daunorubicin hydrochloride, vincristine sulfate, dexamethasone, asparaginase, filgrastim, imatinib mesylate, methotrexate, cytarabine, trimethoprim-sulfamethoxazole, mercaptopurine, leucovorin calcium, alemtuzumab, acyclovir, laboratory biomarker analysis, pharmacological study
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Esophageal Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, Lenvatinib, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Duarte, California • Washington D.C., District of Columbia • Louisville, Kentucky + 10 more
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- irinotecan hydrochloride, leucovorin calcium, fluorouracil, bevacizumab, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, laboratory biomarker analysis
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
- Interventions
- filgrastim, asparaginase, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, ifosfamide, imatinib mesylate, leucovorin calcium, mercaptopurine tablet, methotrexate, pegaspargase, vincristine sulfate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Colorectal Cancer, Cholangiocarcinoma
- Interventions
- Medtronic pump and Codman catheter, Floxuridine (FUDR), Gemcitabine, Oxaliplatin, Irinotecan (CPT-11), Fluorouracil, Anti-EGFR (Panitumumab or Cetuximab)
- Device · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more